OMG this garbage has been run up too fast by the pump n dump crowd! Look at KTRA, this is what happens to these up then back down to reality. Money losing FDA blah blah overvalued
Hi Traders
We can't say much here!
As always history has shown us when a new drug goes on the market we have 3 scenarios:
1 we're going up (green path)
2 the medicine is not good we are going down (red path)
3 we don't know what the medicine is like until many people take it let's go sideways (purple path)
with all that is happening at the moment we are...
Banks has a lot of Long Hedges Open on these tickers, they have been overall short the last 1,5 years.
Now in March they began to close their first Long Hedge position.
Question right now is, did they build up big position yet for the longside, or they just sold their long Hedge and want price to go down further.
If we hold the lows of 0,59 here - no weekly close...
Short squeeze stocks have become a favorite recently. KALA has started getting wrapped into the conversation. Looking at details from sites like FinViz, short float is around 20% meanwhile the float itself shows to be around 42 million shares. Plotting some levels, you'll notice that KALA is still in the lower channel on the fib retracement slowly heading toward...
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to...
Most recent notes from BoA, "KALA provided updates on the preclinical programs, such as tyrosine kinase inhibitor program in retinal diseases (e.g. wet AMD), selective glucocorticoid receptor modulators (SEGRMs) and novel steroids. Mgmt. believes there is high unmet need in areas, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME)...
Looks like history will repeat here. Perfect cup and handle on the daily first go around.. Next 2 months should remain flat then into a move up pending any news.
Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease
-- FDA Sets PDUFA Goal Date of October 30, 202
The idea is to go long hoping to get the good news from the FDA.
NASDAQ:KALA
KALA PHARMACEUTICALS INC $KALA is forming a CUP & Handle formation with a leading BO on the OBV index. The stock had also a lot of insider buying power and positive news with their EYSUVIS (a dry eye disease)
Clinical trial for EYSUVIS (KPI-121) - top line results of Phase III expected on first Q of 2020.
The concern is :
cash position as of September 30 was $97.6 million, compared to $170.9 million as of December 31, 2018.
I do not suggest to buy\sell .
Good-luck
